Advise Saving the New Tetracycline Nuzyra as a Last Resort
Nuzyra (noo-ZYE-rah, omadacycline) will be a once-daily tetracycline antibiotic for community-acquired pneumonia or skin infections.
Nuzyra is effective against some bacteria resistant to doxycycline or minocycline. It will be touted to reduce hospital stays...since patients can start with the IV form and be discharged on the oral tabs.
But Nuzyra doesn't seem more effective than other appropriate antibiotics...and costs about $400/oral dose. Plus it has a warning about a higher rate of death than moxifloxacin in patients with pneumonia...FDA is requiring ongoing studies to tease this out.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote